abstract |
In one aspect, the present invention provides a new method of treating B cell mediated immune disorders. The present invention relates to the treatment of B cell mediated immune disorders such as rheumatoid arthritis, systemic lupus erythematosus, diabetes, and multiple sclerosis. In particular, the present invention relates to the treatment of B cell mediated immune disorders using antibodies that bind to membrane-bound free light chains expressed on the surface of plasma cell precursors. [Selection figure] None |